Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2005-10-21
2009-12-01
Seaman, D. Margaret (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S302000, C514S303000, C514S393000, C544S253000, C544S256000, C544S255000, C546S113000, C546S115000, C546S118000
Reexamination Certificate
active
07625922
ABSTRACT:
The present invention pertains to certain imidazo[4,5-b]pyridin-2-one and oxazolo[4,5-b]pyridin-2-one compounds and analogs thereof, which, inter alia, inhibit RAF (e.g., B-RAF) activity, inhibit cell proliferation, treat cancer, etc., and more particularly to compounds of the formula (I): wherein: J is independently —O— or —NRN1—; RN1, if present, is independently —H or a substituent; RN2is independently —H or a substituent; Y is independently —CH═ or —N═; Q is independently —(CH2)j—M—(CH2)k— wherein: j is independently 0, 1 or 2; k is independently 0, 1, or 2; j+k is 0, 1, or 2; M is independently —O—, —S—, —NH—, —NMe—, or —CH2—; each of RP1, RP2, RP3, and RP4is independently —H or a substituent; and additionally RP1and RP2taken together may be —CH═CH—CH═CH—; L is independently: a linker group formed by a chain of 2, 3, or 4 linker moieties; each linker moiety is independently —CH2—, —NRN—, —C(═X)—, or —S(═O)2—; exactly one linker moiety is —NRN—, or: exactly two linker moieties are —NRN—; exactly one linker moiety is —C(═X)—, and no linker moiety is —S(═O)2—; or: exactly one linker moiety is —S(═O)2—, and no linker moiety is —C(═X)—; no two adjacent linker moieties are —NRN—; X is independently ═O or ═S; each RNis independently —H or a substituent; A is independently: C6-14carboaryl, C5-14heteroaryl, C3-12carbocyclic, C3-12heterocyclic; and is independently unsubstituted or substituted; and pharmaceutically acceptable salts, solvates, amides, esters, ethers, N-oxides, chemically protected forms, and prodrugs thereof. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit RAF (e.g., B-RAF) activity, to inhibit receptor tyrosine kinase (RTK) activity, to inhibit cell proliferation, and in the treatment of diseases and conditions that are ameliorated by the inhibition of RAF, RTK, etc., proliferative conditions such as cancer (e.g., colorectal cancer, melanoma), etc.
REFERENCES:
patent: 5521073 (1996-05-01), Davis et al.
patent: 5877020 (1999-03-01), Alitalo
patent: 5879672 (1999-03-01), Davis et al.
patent: 6030831 (2000-02-01), Godowski et al.
patent: 6258809 (2001-07-01), Rajagopalan et al.
patent: 6492529 (2002-12-01), Kapadia et al.
patent: 2004/0082583 (2004-04-01), Cheung et al.
patent: 56-65863 (1981-06-01), None
patent: 57-038777 (1982-03-01), None
patent: WO 99/16438 (1999-04-01), None
patent: WO 99/21859 (1999-05-01), None
patent: WO 01/36383 (2001-05-01), None
patent: WO 03/056036 (2003-07-01), None
patent: WO 2004/014300 (2004-02-01), None
Itaya et al., Tetrahedron Letters (1998), 39(26), 4695-4696.
Adams, R.H., et al, 1999, “Roles of ephrinB ligands and EphB receptors in cardiovascular development: demarcation of arterial/venous domains, vascular morphogenesis, and sprouting angiogenesis”,Genes Dev., vol. 13, pp. 295-306.
Ananthanarayanan, C., et al, 1988, “Reaction of azidees in presence of aluminum chloride”,Indian Journal of Chemistry, Section B, vol. 27B, pp. 156-157.
Angerer, L.M., et al, 1987, “Demonstration of tissue-specific gene expression by in situ hybridization”,Method in Enzymology, vol. 152, pp. 649-661.
Auvray, P., et al, 1988, “Preparation and nucleophilic substitution of (E)-1-bromo-2-phenylsulfonyl-2-alkenes and 3-acetoxy-2-phenylsulfonyl-1-alkenes”,Tetrahedron, vol. 44, pp. 6095-6106.
Avenoza, A., et al, 1995, “New efficient synthesis of 4-amino-3-arylphenols”,Synthesis, pp. 671-674.
Ballesteros, P., et al, 1987, “Study of the catalytic properties of tris (2,6-dioxaheptyl) amine (TDA-1) in heteroaromatic nucleophilic substitution of chloropyridines and their N-oxides”,Tetrahedron, vol. 43, pp. 2557-2564.
Bhatt, D.J., et al, 1980, “Preparation of N′-2-phenyl-4-quinolinoyl-N3-aryl thioureas”,J. Instit. Chem. (India), vol. 52, pp. 113-114.
Bianchi, M., et al, 1981, “Compounds with antiulcer and antisecretory activity”,Eur. J. Med. Chem., vol. 16, pp. 321-326.
Borthakur, N., et al, 1995, “New direct synthesis of thioamides from carboxylic acids”,Tetrahedron Letters, vol. 36, pp. 6745-6746.
Broekhof, N., et al, 1981, “Novel applications of α-aminosubstituted diphenylphosphine oxides. The conversion of aldehydes into α-aminomethylketones”,Tetrahedron Letters, vol. 22, pp. 2799-2802.
Brooks, P.C., et al, 1994, “Integrin αVβ3antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels”,Cell, vol. 79, pp. 1157-1164.
Brose, M.S., et al, 2002, “BRAFandRASmutations in human lung cancer and melanoma”,Cancer Research, vol. 62, pp. 6997-7000.
Brückner, K., et al, 1997, “Tyrosine phosphorylation of transmembrane ligands for Eph receptors”,Science, vol. 275, pp. 1640-1643.
Bruder, J.T., et al, 1992, “Serum-, TPA-, and Ras-induced expression from Ap-1/Ets-driven promotors requires Raf-1 kinase”,Genes&Development, vol. 6, pp. 545-556.
Cantrell, D.A., 2003, “GTPases and T cell activation”,Immunological Reviews, vol. 192, pp. 122-130.
Chan, A.C., et al, 1996, “Regulation of antigen receptor signal tgransdu8ction by protein tyrosine kinases”,Current Opin. Immunol., vol. 8, pp. 394-401.
Clare, B.W., et al, 2001, “Protease inhibitors: synthesis of a series of bacterial collagenase inhibitors of the sulfonyl amino acyl hydroxamate type”,J. Med. Chem., vol. 44, pp. 2253-2258.
Cohen, Y., et al, 2003, “Lack of BRAF mutation in primary uveal melanoma”,Invest. Ophthalmol. Vis. Sci., vol. 44, pp. 2876-2878.
Colville-Nash, P.R., et al, 1992, “Angiogenesis and rheumatoid arthritis: pathogenic and therapeutic implications”,Annals of the Rheum. Dis., vol. 51, pp. 919-925.
Comins, D.L., et al, 1994, “Grignard addition to 1-acyl salts of chiral 4-alkoxypyridines. A new enantioselective preparation of 2-alkyl-2,3-dihydro-4-pyridones”,Tetrahedron Letters,. vol. 35, pp. 7343-7346.
Cooper, J.A., 1994, “Membrane-associated tyrosine kinases as molecular switches”,Sem. Cell Biology, vol. 5, pp. 377-387.
Correia, J., 1978, “Reaction of phenylglyoxal with aniline under acidic conditions”,J. Org. Chem., vol. 43, pp. 3394-3396.
Courtneidge, S.A., et al, 1993, “The Src family of protein tyrosine kinases: regulation and functions”,Development 1993 Supplement, pp. 57-64.
Cowley, S., et al, 1994, “Activation of MAP kinase kinase is necessary and sufficient for PC12 differentiation and for transformation of NIH 3T3 cells”,Cell, vol. 77, pp. 841-852.
Davies, H., et al, 2002, “Mutations of theBRAFgene in human cancer”,Nature, vol. 417, pp. 949-954.
Davis, S., et al, 1996, “Isolation of angiopoietin-1, a ligand for the TIE2 receptor, by secretion-trap expression cloning”,Cell, vol. 87, pp. 1161-1169.
Denekamp, J., 1993, “Review article: angiogenesis, neovascular proliferation and vascular pathophysiology as targets for cancer therapy”,British Journal of Radiology, vol. 66, pp. 181-196.
Dickson, B., et al, 1992, “Raf functions downstream of Ras1 in the sevenless signal transduction pathway”,Nature, vol. 360, pp. 600-603.
DuBois, G.E., 1980, “Amination of aryl sufamate esters. A convenient general synthesis of aliphatic sulfamides”,Journal of Organic Chemistrty, vol. 45, pp. 5373-5375.
Fidler, I.J., et al, 1994, “The implications of angiogenesis for the biology and therapy of cancer metas
Dijkstra Harmen
Gaulon Catherine
Gill Adrian Liam
Marais Richard Malcol
Menard Delphine
Astex Therapeutics Limited
Cancer Research Technology Limited
Nixon & Vanderhye P.C.
Rahmani Niloofar
Seaman D. Margaret
LandOfFree
Imidazo[4,5-b]pyridin-2-one and oxazolo[4,5-b]pyridin-2-one... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Imidazo[4,5-b]pyridin-2-one and oxazolo[4,5-b]pyridin-2-one..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Imidazo[4,5-b]pyridin-2-one and oxazolo[4,5-b]pyridin-2-one... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4126495